| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.34 | $144,194.58 | -24.6% | |
| Oct 17, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 523 | $18.48 | $9,664.88 | -1.5% | |
| Oct 16, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | CEO And Director | Sell | 3,293 | $60.04 | $197,711.72 | -100% | |
| Oct 13, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 3,026 | $18.56 | $56,176.48 | -3.5% | |
| Oct 13, 2017 | LNTH Lantheus Holdings, Inc. | Crowley John W. | CFO | Sell | 6,755 | $18.41 | $124,366.31 | -4.5% | |
| Oct 13, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | CEO And Director | Sell | 7,124 | $60.08 | $428,013.76 | -2.1% | |
| Oct 12, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 7,862 | $18.73 | $147,219.09 | -24.6% | |
| Oct 5, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Gerst Diane G. | EVP, Qa &Regulatory Affairs | Sell | 8,444 | $18.87 | $159,376.28 | -19.7% | |
| Oct 5, 2017 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 63,479 | $3.48 | $221,198.92 | -30.9% | |
| Oct 4, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $86.81 | $17,795,025.00 | -0.2% | |
| Oct 4, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 39,312 | $18.59 | $730,755.04 | -37.8% | |
| Oct 2, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $50.64 | $75,960.00 | -15.8% | |
| Oct 2, 2017 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 63,624 | $18.18 | $1,156,951.54 | -62.5% | |
| Oct 2, 2017 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 7,803 | $19.89 | $155,188.42 | -3.6% | |
| Oct 2, 2017 | NBIX Neurocrine Biosciences Inc | Obrien Christopher Flint | Chief Medical Officer | Sell | 6,925 | $61.04 | $422,702.00 | -12.4% | |
| Oct 2, 2017 | TLPH Talphera, Inc. | Hamel Lawrence G | Chief Development Officer | Sell | 10,161 | $5.29 | $53,751.69 | -19.5% | |
| Oct 2, 2017 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 1,188 | $19.64 | $23,332.32 | -5.0% | |
| Oct 2, 2017 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,398 | $19.64 | $27,456.72 | -1.4% | |
| Sep 29, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 195,000 | $85.14 | $16,602,600.83 | - | |
| Sep 29, 2017 | EBS Emergent Biosolutions Inc. | El-Hibri Fuad | Chairman | Sell | 50,000 | $40.00 | $2,000,000.00 | -1.6% | |
| Sep 28, 2017 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 5,000 | $19.30 | $96,500.00 | -4.9% | |
| Sep 28, 2017 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 23,681 | $40.00 | $947,240.00 | -33.6% | |
| Sep 27, 2017 | EBS Emergent Biosolutions Inc. | Abdun-Nabi Daniel | President &CEO | Sell | 15,000 | $39.92 | $598,770.00 | -6.8% | |
| Sep 27, 2017 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 7,885 | $39.50 | $311,457.50 | -23.2% | |
| Sep 25, 2017 | TLPH Talphera, Inc. | Hamel Lawrence G | Chief Development Officer | Sell | 13,827 | $0.00 | - | -16.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.